IBAT inhibitors SC-435 and A4250 were investigated in Mdr2-/- mice, which is an established model of sclerosing cholangitis (Fickert et al., 2004), and SC-435 was also studied in high-fat diet (HFD)-induced fatty liver disease. Here, SLC10A2 is linked to sclerosing cholangitis.